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Mutations and polymorphisms in the gene-encoding factor H
(CFH) are associated with atypical hemolytic uremic
syndrome, dense deposit disease, and age-related macular
degeneration. Many of these CFH genetic variations disrupt
the regulatory role of factor H, supporting the concept that
dysregulation of complement is a unifying pathogenic
feature of these disorders. Evidence of a causal relationship
with the disease is, however, not available for all CFH genetic
variations found in patients, which is a potential cause of
misinterpretations with important consequences for the
patients and their relatives. CFH I890 and L1007 are two
genetic variations repeatedly associated with atypical
hemolytic uremic syndrome and also found in patients with
dense deposit disease and age-related macular degeneration.
Here we report an extensive genetic and functional analysis
of these CFH variants. Our results indicate that I890 and
L1007 segregate together as part of a distinct and relatively
infrequent CFH haplotype in Caucasians. Extensive analysis of
the S890/V1007 (control) and I890/L1007 (disease-associated)
factor H protein variants failed to provide evidence that these
amino acid changes have functional implications. Thus, the
presence of the I890 and L1007 variants in healthy
individuals and their high frequency in sub-Saharan African
and African-American populations strongly suggest that I890
and L1007 are rare factor H polymorphisms unrelated to
disease.
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Complement factor H (FH) is the main regulator of the
alternative pathway (AP) of the complement system. FH
exerts this regulatory activity in three different ways: it binds
to C3b, competing with factor B in the assembly of the AP
C3-proconvertase complex; it accelerates the decay of the AP
C3-convertase; and functions as a cofactor of factor I (FI) in
the proteolytic inactivation of C3b.1–3 FH regulates comple-
ment activation both in fluid phase and on cellular
surfaces,4–6 preserving complement homeostasis and pre-
venting uncontrolled C3b deposition and host tissue damage.
FH is a relative abundant plasma protein that is secreted as
a single-chain glycoprotein of 155 kDa composed of 20
homologous domains of 60 amino acids,7 named short
consensus repeats (SCRs). FH concentration in plasma is
highly variable, ranging from 116 to 562 mg/ml.8 Different
interaction sites for C3b and polyanions have been identified
along the 20 SCRs of FH. The SCR 1–4 region is the unique
C3b-binding site capable to function as a cofactor for FI in
the cleavage of C3b and to accelerate the decay of AP C3-
convertase.9 Similarly, the C3b- and polyanion-binding site at
SCRs 19–20 determines the ability of FH to bind C3b
deposited on the cell surface, with this region of FH being
essential for self-pathogen discrimination.10,11
Mutations and polymorphisms in the CFH gene are
associated with atypical hemolytic uremic syndrome (aHUS),
dense deposit disease (DDD), and age-related macular
degeneration (AMD; reviewed in ref. 12). The available data
support the hypothesis that AP dysregulation is a unifying
pathogenic feature of these diverse conditions. They also
illustrate a remarkable genotype–phenotype correlation in
which distinct genetic variations at CFH specifically predis-
pose to aHUS, AMD, or DDD. In fact, the functional
characterization of these disease-specific CFH genetic varia-
tions is instrumental to understand the molecular basis
underlying each of these pathologies.
In aHUS, a thrombotic microangiopathy characterized
by thrombocytopenia, hemolytic anemia, and acute renal
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failure, and where endothelial cell injury appears to be the
primary pathogenic event, the most prevalent genetic
alterations in the CFH gene are missense mutations that
alter the C3b- and polyanion-binding site at the C terminus
of FH. These mutations rarely result in hypocomplemente-
mia or decreased FH plasma levels.13–16 Functional studies
have demonstrated that these aHUS-associated FH molecules
present normal regulatory activity in plasma but a limited
capacity to protect cells from complement lysis.17–21 This
functional alteration is clearly distinct from the lack of
complement regulation in plasma, leading to complete C3
consumption and severe hypocomplementemia that char-
acterizes DDD patients.
DDD is a very rare form of glomerulonephritis with
isolated C3 deposits characterized by the presence of dense
deposits within the glomerular basement membrane.22 DDD
is associated with complement abnormalities that lead to
persistent reduction of C3 serum levels and intense deposi-
tion of degradation products of C3 in the glomerular
basement membrane. Among the different factors associated
with these complement abnormalities are mutations in the
CFH gene. These CFH mutations result in truncations or
amino acid substitutions that impair secretion of FH into
circulation or that eliminate the complement regulatory
activities located at the N terminus of FH.23–26 Thus, CFH
mutations that decrease FH in plasma, or eliminate its
complement regulatory activity, lead to unrestricted activa-
tion of complement in plasma, causing damage to glomerular
cells and deposition of complement products in the
glomerular basement membrane.
Age-related macular degeneration, the most common
cause of blindness in the elderly in developed countries, is
characterized by drusen, lipoproteinaceous deposits localized
between the retinal pigment epithelium and Bruch’s mem-
brane, which leads to an extensive atrophy of the retinal
pigment epithelium and overlaying photoreceptor cells
(geographic atrophy) or aberrant choroidal neovasculariza-
tion under the macular area. AMD and DDD share
pathological similarities with accumulation of complement-
containing debris within the eye and kidney, respectively.
Indeed, AMD-like pathology is well recognized in patients
with DDD.27 The identification of CFH as a major
susceptibility locus for AMD and the characterization of
multiple genetic variants in the CFH genomic regions
conferring risk or protection to AMD indicate that the
complement system has a significant role in AMD pathogen-
esis.28–32 However, CFH association data showed no
overlapping between CFH at-risk polymorphisms for aHUS
and AMD.20
The peculiar genotype–phenotype correlation between
specific CFH genetic variations and a particular disease
contrast with the situation of the CFH I890 and L1007
variations (in SCR 15 and SCR 17, respectively) that have
been repeatedly reported to be associated with aHUS and are
also found in DDD and AMD patients.31,33–35 To characterize
the functional consequences of these CFH genetic variations,
we have purified the different FH protein variants to
homogeneity from the plasma of appropriate carriers and
tested their capacity to bind to surface-bound C3b, analyzed
their cofactor activity in the FI-mediated inactivation of
fluid-phase C3b, and performed FH-dependent hemolytic
assays. None of these assays showed functional alterations in
the regulatory activity of the FH, which strongly suggest that
they are rare FH polymorphisms without functional
consequences.
RESULTS
Sequencing analyses of the CFH gene in the aHUS (n¼ 259)
and DDD (n¼ 19) Spanish cohorts identified four aHUS
patients (H54, H97, H142, and H244) and one DDD patient
(GN3) carrying two nucleotide changes (c.2669 G4T; S890I
and c.3019 G4T; V1007L) in heterozygosis. The same c.2669
G4T and c.3019 G4T nucleotide changes were also detected
in heterozygosis in 2 out of 173 controls, an occurrence that
is not significantly different from that found in patients.
Complement profiles and clinical data of the aHUS and DDD
patients carrying the S890I and V1007L amino acid changes,
as well as additional genetic alterations in other complement
genes found in these patients, are summarized in Table 1.
Two aHUS pedigrees were available for segregation
analysis. In both cases it was demonstrated that the patients
inherited both nucleotide changes (c.2669 G4T and c.3019
G4T) from the same progenitor, illustrating that they were
carried by the same CFH allele. Further analyses of several
single-nucleotide polymorphisms within the CFH gene
demonstrated that, in all carriers, these I890 and L1007
amino acid changes associated with the same CFH haplotype,
suggesting a single evolutionary origin for the I890/L1007
CFH haplotypes identified in the aHUS, DDD, and control
individuals (Table 2). Interestingly, the I890/L1007 CFH
haplotype carries the AMD and DDD risk polymorphism
His402, which may have implications for its association with
AMD and DDD. The I890/L1007 CFH haplotype is probably
old. This is supported by the existence of I890/L1007 CFH
‘recombinant’ haplotypes, such as that of H97, affecting the
50 end region of CFH, or the genomic rearrangement that
resulted in the generation of the CFHHCFHR1 hybrid gene in
H142.
As indicated, the I890/L1007 CFH haplotype in H142 is
remarkable because, in addition, it encodes a CFHHCFHR1
hybrid gene that resulted from a nonhomologous recombi-
nation between the CFH and CFHR1 genes. Thus, the FH
protein encoded by this CFH allele carries a total of four
amino acid changes compared with a normal CFH allele: I890
and L1007 and another two (L1191 and A1197) characteristic
of the exon 6 of CFHR1, which replaces the exon 23 of CFH
in the CFHHCFHR1 hybrid gene (Table 2).36
To purify the I890/L1007 FH variant from nonmutated FH
in heterozygote carriers, we used affinity chromatography
with the MBI-7 anti-human FH monoclonal antibody.37,38
This antibody specifically recognizes the H402 variant of FH,
and was used to capture the FH allele carrying the I890 L1007
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amino acid changes from the plasma of patients H54 and
H142, who are FH Y402H heterozygotes. The eluted protein
was further purified by gel filtration and concentrated, free of
contaminants. We followed the same protocol to purify the
S890/V1007 FH allele from control FH Y402H heterozygote
donors (Figure 1). After quantification by enzyme-linked
immunosorbent assay (ELISA), the purified proteins, S890/
V1007, I890/L1007, and I890/L1007/L1191/A1197, were
tested functionally in a number of different assays.
To test whether the I890/L1007 amino acid changes affect
the cofactor activity for the FI-mediated proteolysis of C3b,
S890/V1007 and I890/L1007 FH variants were mixed with
C3b and incubated in the presence of FI at 37 1C. After
densitometric analysis of Coomassie-stained gels, the ratio
between a0-chain and b-chain of C3b was used to calculate
the percentage of C3b cleavage. As illustrated, no differences
in the cofactor activities between FH variants S890/V1007
and I890/L1007 (Figure 2a and b) or between S890/V1007
and I890/L1007/L1191/A1197 (Figure 2a–c) were appreciated,
indicating that these amino acid substitutions do not have a
significant effect on the cofactor activity of FH. As a control
that our assays have appropriate sensitivity to detect small
functional alterations we have included in these experiments
the V62 and I62 FH polymorphic variants, which we
previously showed that present slightly differences in their
FI cofactor activities.39
To explore the effect of the I890/L1007 amino acid changes
in the interaction with C3b, we performed a C3b-binding
plate assay. Purified C3b was immobilized on microtiter
plates and identical quantities of the I890/L1007 and
Table 1 | Clinical and complement data of patients carrying the CFH I890 and L1007 genetic variants
aHUS DDD
H54a H97 H142b H244c GN3d
Age at onset (years) 51 41 3.5 1 5.5
C3 (70–140mg/dl) 59 123 94.3 135 135
C4 (14–47mg/dl) 7 24.5 24.2 31.5 31.5
Total FH (116–562mg/ml) 127.4 256.8 150 316 161.8
% FHI890L1007
e 46 47 56 — —
FI (75–115%)f 99 52 104 80 103
Additional mutations None CFI C86Y CFHHCFHR1 hybrid gene None None
Del CFHR1–CFHR3 None None Het None None
Autoantibodies None None None None C3Nef
Renal status (outcomes) Deceased ESRD ESRD MRI MRI
Transplantation (recurrences) None Yes (no) Yes (no) None None
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AMD, age-related macular degeneration; C3Nef, C3 nephritic factor; DDD, dense deposit disease; ESRD, end-stage
renal disease; FH, complement factor H; FI, factor I; GBM, glomerular basement membrane; Het, heterozygous; MRI, moderate renal insufficiency.
aMale patient who was diagnosed of post-transplant HUS (microangiopathic hemolytic anemia with schistocytes, and renal failure) associated with tacrolimus and cyclosporin
treatment. He died 1 month later from pneumonia caused by acinetobacter and aspergillus.
bAfter almost 4 years of hemodialysis, this male patient received a cadaver kidney transplantion on September 2010. He was treated with eculizumab (Soliris) before
transplantation and every 15 days afterward, following the protocol recommended by Alexion Pharmaceuticals, Cheshire, CT. He is actually in good condition.
cThis is a male child from Nigeria. He developed HUS after diarrhea and a respiratory infection. He was under peritoneal dialysis and recovered partial renal function. No
recurrences. Actually present moderate renal insufficiency.
dDiagnosis of DDD in this patient was established on the basis of renal biopsy (light microscopy, immunofluorescence, and electron microscopy (EM)) performed at
presentation of the disease. Moderate mesangial hypercellularity and increased mesangial matrix without double contour in the capillary walls was observed.
Immunofluorescence showed intense isolated granular C3 staining in the capillary walls and in the mesangium in the form of nodular rings, negative for immunoglobulins or
other complement proteins. EM revealed abundant electron-dense ribbon-like deposits within the GBM and local electron-dense deposits in the mesangium. The
presentation was a nephritic syndrome with microhematuria and without proteinuria. He showed persistence hypocomplementemia C3 (8mg/dl) and 4 months after was
C3NeF-positive. This situation was maintained for 12 years. In 1992, at the age of 20 years, he presented proteinuria 5.75 g/day; serum creatinine: 1.0mg/dl; creatinine
clearance: 147ml/min, and remained C3Nef-positive. He was treated with prednisone. By 2007, after 33 years of evolution, the C3Nef titers were only detected as traces, with
normalization of C3 levels and with an almost complete remission of the proteinuria after combined angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor
blocker (ARB) therapy. He presented ocular manifestations of AMD (drusen) at the age of 33 years. The patient actually presented a moderate renal insufficiency (creatinine:
1.9mg/dl; creatinine clearance: 65ml/min) and proteinuria 1.2 g/day.
eIn FH His402Tyr heterozygotes, levels of expression of the FHI890L1007 allele were determined by enzyme-linked immunosorbent assay using anti-FH 402His-specific
antibodies.37
fFactor I levels are referred to a reference pool of sera.
Table 2 |CFH haplotypes carrying the FH I890 and L1007 amino acid substitutions
Promoter
-332 C4T
V62I
c.184 G4A
Y402H
c.1204 T4C
Q672Q
c.2016 A4G
E936D
c.2808 G4T
S890I
c.2669 G4T
V1007L
c.3019 G4T
S1191
c.3645 C
V1197
c.3663 T
N1 C G C A G T T C T
N2 C G C A G T T C T
H54 C G C A G T T C T
H244 C G C A G T T C T
GN3 C G C A G T T C T
H97 C A C A G T T C T
H142 C G C A G T T T C
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S890/V1007 FH variants were added and allowed to interact
for 2 h at 37 1C. FH bound to C3b was detected using the
Ox24 monoclonal antibody. FH was quantified in parallel in
the same ELISA experiment. Our results show that the
binding to C3b of the purified FH protein I890/L1007 was
undistinguishable from that of the control FH S890/V1007
(Figure 3). These results indicate that the amino acid changes
in the SCRs 15 and 17 do not alter the capacity of FH to bind
C3b. We also used in these experiments the V62 and I62 FH
polymorphic variants, as it has also been shown previously
that they present slight differences in their C3b-binding
capacity39 (Figure 3).
To investigate the potential effect of the I890 and L1007
amino acid changes in the regulatory activity of FH on cell
surfaces, the S890/V1007 and I890/L1007 FH variants were
tested in an FH-dependent hemolytic assay developed in our
laboratory. In these assays, a human serum sample carrying a
well-characterized CFH mutation, which alters the C
terminus of FH,18 was reconstituted with identical amounts
of the S890/V1007, I890/L1007, or I890/L1007/L1191/A1197
FH variants and incubated with sheep erythrocytes in the
presence of 7 mmol/l Mg2þ and ethylene glycol tetraacetic
acid. Lysis of erythrocytes in this assay inversely correlates
with the capacity of FH to regulate the AP on the cellular
surface. Our results indicate that the I890/L1007/L1191/
A1197 FH variant presents decreased inhibition of the
erythrocyte lysis compared with the native nonmutated
variant of FH (Figure 4b). This reduced capacity to regulate
the AP on the cellular surface was expected because this FH
variant is also the product of a CFHHCFHR1 hybrid gene.36
In contrast, the FH variant from H54 showed no difference
with the FH control and demonstrated to function efficiently
in the protection against erythrocyte lysis (Figure 4a). These
data, again, indicate that the S890I and V1007L amino acid
substitutions are not altering the capacity of FH to regulate
the complement AP on the cellular surface.
DISCUSSION
Mutation screening of complement genes in aHUS, DDD,
and AMD has become a laboratory routine. Identification of
mutations helps diagnosis and provides useful information to
anticipate the evolution of the disease in the patients and
their response to treatments, conditioning clinical decisions.
For example, among aHUS patients, those carrying CFH
mutations have the worse prognosis and poorest renal
transplantation outcomes, although they associate with good
responses to plasma treatment. In addition, identification of
mutations and polymorphisms associated with increased risk
to these pathologies also influence the genetic counseling
provided to patients and their relatives. It is therefore critical
to obtain evidence supporting the fact that the disease-
associated mutations identified in these screenings have a
causal relationship with the pathology. Here we have studied
two FH amino acid substitutions, I890 and L1007, lacking
this functional information that has repeatedly been found
among Spanish aHUS and DDD patients and that has also
been reported to be associated with aHUS in other Caucasian
cohorts.33–35 In addition, S890I and V1007L were described as
rare polymorphisms associated with AMD.31,35
The peculiar concurrence of both S890I and V1007L
amino acid substitutions in all these cases is explained by the
segregation analysis performed here in two aHUS pedigrees
that revealed that these two amino acid changes segregate
together with a unique CFH haplotype characterized by a
specific combination of single nucleotide polymorphisms
(Table 2). The high allelic frequency of the S890I and V1007L
polymorphisms in sub-Saharan African (0.267; 0.317) and
African-American (0.455; 0.591) populations (rs515299 and
rs534399, respectively) suggest that this CFH haplotype has
an African origin and was introduced in Caucasians some
time ago. In support of this conclusion, one of the patients in
our cohort carrying this haplotype (H244) is of sub-Saharan
African origin.
Carriers of the I890/L1007 CFH haplotype present normal
FH levels in plasma with a contribution of the I890/L1007 FH
allele of approximately 50% (Table 1). These data illustrate
that these amino acid substitutions do not influence the
expression/secretion of FH. To characterize the potential
consequences of the S890I and V1007L substitutions in the
functional activities of FH, we performed three different
functional assays using purified FH proteins. We tested the
capacity of the I890/L1007 FH variant to bind to surface-
bound C3b, analyzed its cofactor activity in the FI-mediated
kDa
S8
90
/V
10
07
I8
90
/L
10
07
I8
90
/L
10
07
L1
19
1/
A1
19
7
250
150
100
75
Figure 1 | SDS-PAGE Coomassie-stained gel of the purified FH
variants. The S890/V1007, I890/L1007, or I890/L1007/L1191/
A1197 factor H (FH) variants were purified from the plasma of a
healthy individual and the atypical hemolytic uremic syndrome
(aHUS) patients H54 and H142, as described in Materials and
Methods.
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inactivation of fluid-phase C3b, and performed an FH-
dependent hemolytic assay to determine its capacity to
regulate the AP on cellular surfaces. None of these assays
showed functional alterations in the regulatory activity of
FH. This failure to detect functional alterations caused by the
S890I and V1007L substitutions is not a consequence of a
lack of sensitivity of our assays. They clearly revealed the
subtle functional differences caused by the FH Val62Ile
polymorphism or by the modification of the C-terminal
region of FH that occurs in the CFHHCFHR1 hybrid
gene.36,39 We therefore concluded that the FH S890I and
V1007L variants are most likely CFH polymorphisms without
functional consequences. Furthermore, recent structural data
have shown that SCR15 and SCR17, including these
variations, are not implicated in the interaction between
FH and C3b.40
Carriers of the I890/L1007 CFH haplotype in the Spanish
aHUS cohort present other well-characterized mutations
and/or polymorphisms in complement genes that may help
to explain the development of the disease in these
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Figure 2 |Cofactor activity of FH variants in the proteolysis of fluid-phase C3b. C3b and factor I (FI) were incubated with equal amounts
of S890/V1007, I890/L1007, or I890/L1007/L1191/A1197 factor H (FH) variants for 10min at 37 1C and the reaction was stopped by the
addition of SDS sample buffer. Samples were analyzed by SDS-PAGE under reducing conditions, and gels were stained with Coomassie (a). A
densitometric analysis of C3b proteolysis from triplicates of these experiments is shown in (b). A time-course analysis of C3b proteolysis is
shown in (c). Fluid-phase cofactor activity was measured by examining C3b cleavage at 2.5, 5, 7.5, and 10min of reaction for both control
S890/V1007 (filled triangles) and I890/L1007/L1191/A1197 (open triangles) FH variants. Percentage of cofactor activity was determined by
the ratio of C3b-cleaved, a0-chain/b-chain, and normalized to 0% proteolysis of control samples. Inset panel shows the double reciprocal
plot of the S890/V1007 and I890/L1007/L1191/A1197 of the cofactor activity curves. Multiple linear regression analysis showed no
significant differences between the slopes for S890/V1007 and I890/L1007/L1191/A1197 cofactor activities. The sensitivity of our assay was
demonstrated by including in the experiment a S890/V1007 FH carrying the I62 polymorphism (open circles).
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Figure 3 |Capacity of the FH variants to bind to C3b.
The interaction between serial dilutions of purified factor H (FH)
and C3b deposited in 96-well plates is expressed as percentage
of the amount of S890/V1007 FH variant bound to C3b at a
concentration of 2.5mg/ml. Means±s.d. of three independent
experiments are shown for S890/V1007 (filled triangles),
I890/L1007 (open triangles) FH variants, and for a S890/V1007 FH
variant carrying the I62 polymorphism (open circles). The last
sample illustrates the sensitivity of our assay.
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individuals. Thus, patient H54 carries in homozygosis the
aHUS-conferring risk allele MCPggaac;
41 patient H97 also
carries in homozygosis the MCPggaac allele and, in addition,
the mutation C86Y in the CFI gene, which produces a partial
deficiency of FI in plasma (Table 1); and in patient H142, the
I890/L1007 CFH haplotype also carries a CFHHCFHR1
hybrid gene, which produces a FH protein with reduced
capacity to regulate the AP on cellular surfaces (Figure 4b).36
Similarly, patient GN3 is positive for C3 nephritic factor.
Finally, an increased frequency of the I890/L1007 CFH
haplotype in DDD and AMD should be expected because this
CFH haplotype also carries the CFH H402 allele (rs1061170),
a very strong risk factor for both AMD and DDD.20,28
In conclusion, we failed to provide evidence supporting a
causal relationship of I890/L1007 with aHUS. The lack of
functional consequences of the CFH S890I and V1007L
amino acid substitutions, their presence in healthy individ-
uals, and their very high frequency in sub-Saharan African
and African-American populations strongly suggest that
S890I and V1007L are rare FH polymorphisms unrelated
with the disease.
MATERIALS AND METHODS
Complement analysis, mutation screening, and genotyping
C3 and C4 concentrations were determined by nephelometry
(Immage, Beckman Coulter, Brea, CA) and FH plasma concentration
was quantified by a specific sandwich ELISA method using polyclonal
and monoclonal antibodies developed in-house, which do not cross-
react with the CFHRs proteins. C3 nephritic factor was measured
in serum plasma by standard procedures.42 Patients and healthy
volunteers were screened for mutations and polymorphisms in the
CFH, MCP, CFI, CFB, C3, and THBD genes by automatic DNA
sequencing of PCR-amplified fragments. Genomic DNA was prepared
from peripheral blood cells according to standard procedures. Each
exon was amplified from genomic DNA by using specific primers
derived from the 50 and 30 intronic sequences as described.15,43–45
Automatic sequencing was performed in an ABI 3730 sequencer using
a dye terminator cycle sequencing kit (Applied Biosystems, Foster City,
CA). Copy number variations in the CFHR1-R3 genes were analyzed
by multiplex ligation-dependent probe amplification as described.46
The studies described herein received IRB approval (Comision de
Bioetica, Consejo Superior de Investigaciones Cientı´ficas and CEIC,
Hospital Universitario La Paz, Madrid, Spain). Patients and their
relatives gave their informed consent.
Proteins
FH allele carrying the mutations I890 and L1007 was isolated from
fresh plasma of aHUS patient H54 and a relative of the aHUS
patient H142. We used a CNBr-activated sepharose 4B (GE
Healthcare, Little Chalfont, UK) column coupled with the mono-
clonal antibody MBI-7 that exclusively recognizes the FH H402
protein variant.37,38 Fractions containing FH were collected,
concentrated, and applied to a gel-filtration column (Superose 6,
GE Healthcare). Fractions containing the FH were pooled and the
purity of final preparations was confirmed in SDS-PAGE Coomas-
sie-stained gels (Figure 1). C3 was purified by affinity chromatog-
raphy and gel filtration as described previously.47 C3b was generated
by limited digestion with trypsin and re-purified by gel filtration
as described above. C3b was obtained without any detectable
contaminants or aggregates. Factor I was purchased from Comptech
(Tyler, TX). Concentration of sample proteins was assessed using
absorbance at 280 nm, and molarities were calculated using an
extinction coefficient for CFH of 1.95 (ref. 37) and for C3 of 0.98
(Protean Software, DNAStar, Madison, WI).
Cofactor activity for FI-mediated proteolysis of fluid-phase
C3b
The fluid-phase cofactor activity of FH was determined in a C3b
proteolysis assay using purified proteins. In brief, C3b, FH, and FI
were mixed in 10 mmol/l Hepes, pH 7.5, 150 mmol/l NaCl, and
0.02% Tween 20 at final concentrations of 50, 4, and 2.5 mg/ml,
respectively. Mixtures were incubated at 37 1C for 10 min. In another
set of assays, samples were collected at 2.5, 5, 7.5, and 10 min of
incubation. The reactions were stopped by the addition of 3 ml of
SDS sample buffer (2% SDS, 62.5 mmol/l Tris, 10% glycerol, and
0.75% bromophenol blue). Samples were analyzed in 10%
SDS-PAGE under reducing conditions. Gels were stained with
Coomassie brilliant blue R-250 (BioRad, Berkeley, CA) and
proteolysis of C3b determined by measuring the cleavage of the
a0-chain using a GS-800 calibrated densitometer (BioRad) and the
MultiGauge software package (Fujifilm, Fujifilm Europe GmbH,
Barcelona, Spain). The C3b b-chain was used as an internal control
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Figure 4 | Inhibition of the lysis of sheep erythrocytes by the FH variants. A volume of serum from a control patient carrying a well-
characterized mutation in CFH giving 100% lysis when added to sheep erythrocytes was mixed with different amounts of the purified factor
H (FH) variants. The lysis observed is shown as percentage of the lysis in the absence of added FH and was plotted against added FH.
Means±s.d. of three independent experiments are shown for S890/V1007 (open circles) and I890/L1007 (filled circles) (a), and for
S890/V1007 (open circles) and I890/L1007/L1191/A1197 (filled circles) FH variants (b). Statistical differences are as follows: *Po0.05;
**Po0.01; ***Po0.001.
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to normalize the amount of protein added between samples.
Percentage of cleavage was determined by the ratio between a0-chain
and b-chain of C3b and setting as 0% of proteolysis by using a
control FH in the absence of FI.
ELISA C3b-binding assay
The binding of FH variants to surface-bound C3b was determined
by ELISA method. Polystyrene microtiter plates (96 well) were
coated with C3b (2.5 mg/ml) in coupling buffer (0.1 M NaHCO3, pH
9.5) overnight at 4 1C. The plate was blocked with washing buffer
(20 mmol/l Tris, 150 mmol/l NaCl, and 0.1% Tween 20) with 1%
bovine serum albumin for 1 h at room temperature. After washing,
serial dilutions of FH variants (starting dilution was 2.5 mg/ml) were
added and incubated with surface-bound C3b for 2 h at 37 1C. After
washing, the plate was incubated with anti-FH monoclonal antibody
Ox24 for 1 h at room temperature, and then with a secondary
antibody coupled with horseradish peroxidase (DAKO, Glostrup,
Denmark). Color reaction was developed with O-phenylenediamine
(DAKO) and absorbance measured at 492 nm. FH preparations used
in the ligand assay were quantified in duplicate in the same ELISA
plate using immobilized polyclonal anti-FH antibody to capture FH,
followed by the Ox24 and secondary antibodies to measure the
amount of FH. Concentrations of FH were calculated from curves
obtained using purified standard samples.
Factor H-dependent hemolytic assay
The capacity of FH to regulate the activity of the AP on cellular surfaces
was assessed with a hemolytic assay using sheep erythrocytes and a
serum carrying a well-characterized CFH mutation, FH-W1183L.18
In brief, 1 107 sheep erythrocytes in AP buffer: veronal buffer saline
(2.5 mmol/l barbital, 1.5 mmol/l sodium barbital, 144 mmol/l NaCl,
pH 7.4) with 7 mmol/l MgCl2 and 10 mmol/l ethylene glycol tetraacetic
acid, were incubated with 10% FH-W1183L serum in AP buffer and
increasing amounts of the different FH variants for 30 min at 37 1C.
The reaction was stopped by adding veronal buffer saline containing
20 mmol/l EDTA. After centrifugation, supernatants were read at
414 nm. FH variants I890/L1007 and I890/L1007/L1191/A1197 were
compared with the same control FH variant, S890/V1007, in two
independent assays. FH-W1183L serum without added FH was taken
as 100% of lysis and serum diluted in AP buffer plus 20 mmol/l EDTA
was used as blank for spontaneous lysis.
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